$SPRO Spero Therapeutics, Inc. Insider Trading Week 45/2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Spero Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Spero Therapeutics, Inc. in week 45/2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Option Exercise | C | 0.00 | 3,683,045 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Option Exercise | C | 0.00 | 1,250,000 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Option Exercise | C | 0.00 | 982,906 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Option Exercise | C | 0.00 | 1,483,784 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Buy | P | 14.00 | 428,571 | 5,999,994 | 1,854,006 | 1.4 M to 1.9 M (+30.07 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Buy | C | 0.00 | 606,024 | 0 | 1,425,435 | 819.4 K to 1.4 M (+73.96 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Buy | C | 0.00 | 328,992 | 0 | 819,411 | 490.4 K to 819.4 K (+67.08 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Buy | C | 0.00 | 246,272 | 0 | 490,419 | 244.1 K to 490.4 K (+100.87 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | GLAXOSMITHKLINE PLC | 10% Owner | Buy | C | 0.00 | 244,147 | 0 | 244,147 | 0 to 244.1 K |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 3,662,178 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 3,119,633 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 1,250,000 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 982,906 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 1,492,645 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Buy | P | 14.00 | 428,571 | 5,999,994 | 2,408,128 | 2 M to 2.4 M (+21.65 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 602,589 | 0 | 1,979,557 | 1.4 M to 2 M (+43.76 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 513,318 | 0 | 1,376,968 | 863.7 K to 1.4 M (+59.44 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 328,992 | 0 | 863,650 | 534.7 K to 863.7 K (+61.53 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 246,272 | 0 | 534,658 | 288.4 K to 534.7 K (+85.40 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 245,605 | 0 | 288,386 | 42.8 K to 288.4 K (+574.10 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Goyal Vikas | Director | Option Exercise | C | 0.00 | 3,683,045 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Goyal Vikas | Director | Option Exercise | C | 0.00 | 1,250,000 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Goyal Vikas | Director | Option Exercise | C | 0.00 | 982,906 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Goyal Vikas | Director | Option Exercise | C | 0.00 | 1,483,784 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Goyal Vikas | Director | Buy | P | 14.00 | 428,571 | 5,999,994 | 1,854,006 | 1.4 M to 1.9 M (+30.07 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Goyal Vikas | Director | Buy | C | 0.00 | 606,024 | 0 | 1,425,435 | 819.4 K to 1.4 M (+73.96 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Goyal Vikas | Director | Buy | C | 0.00 | 328,992 | 0 | 819,411 | 490.4 K to 819.4 K (+67.08 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Goyal Vikas | Director | Buy | C | 0.00 | 246,272 | 0 | 490,419 | 244.1 K to 490.4 K (+100.87 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Goyal Vikas | Director | Buy | C | 0.00 | 244,147 | 0 | 244,147 | 0 to 244.1 K |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Sendek Joel | Chief Financial Off ... | Option Exercise | C | 0.00 | 61,880 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Sendek Joel | Chief Financial Off ... | Buy | P | 14.00 | 5,000 | 70,000 | 15,181 | 10.2 K to 15.2 K (+49.11 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Sendek Joel | Chief Financial Off ... | Buy | C | 0.00 | 10,181 | 0 | 10,181 | 0 to 10.2 K |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Larkin Cristina | Chief Operating Off ... | Buy | P | 14.00 | 1,500 | 21,000 | 1,500 | 0 to 1.5 K |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Breum Casper | Director | Option Exercise | C | 0.00 | 2,485,272 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Breum Casper | Director | Option Exercise | C | 0.00 | 681,818 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Breum Casper | Director | Option Exercise | C | 0.00 | 1,153,846 | 0 | 0 | |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Breum Casper | Director | Buy | P | 14.00 | 214,285 | 2,999,990 | 1,091,774 | 877.5 K to 1.1 M (+24.42 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Breum Casper | Director | Buy | C | 0.00 | 408,937 | 0 | 877,489 | 468.6 K to 877.5 K (+87.28 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Breum Casper | Director | Buy | C | 0.00 | 179,450 | 0 | 468,552 | 289.1 K to 468.6 K (+62.07 %) |
| Nov 07 2017 | SPRO | Spero Therapeutics ... | Breum Casper | Director | Buy | C | 0.00 | 289,102 | 0 | 289,102 | 0 to 289.1 K |